Thorsten Leucker
@tleucker
Preventive and Critical Care Cardiologist, Vascular Biologist, Director, Cardiology Fellowship Program @HopkinsMedicine
ID: 1164867553266524161
23-08-2019 11:50:52
122 Tweet
841 Takipçi
307 Takip Edilen
Better preserved myocardial energetics detected by non-invasive cardiac 31P MRS in HFrEF predicts future LVEF recovery, LV reverse remodeling, and clinical hard outcomes (cardiac death, LVAD, or transplant). Our paper just out in Circulation! ahajournals.org/doi/10.1161/CI…
Thank you very much Roger Blumenthal !!! Appreciate your support and mentorship!
Thank you Allison G. Hays, MD !!! Appreciate all your help and guidance!
Very appreciative of your mentorship and support along the way Roger Blumenthal Wendy Post 🙏🏻
Very well deserved Efthymios (Timos) Ziogos !!! Very proud of all your past achievements! Can’t wait to see what the future holds for you!
#ESCCongress2024 🫀London with the amazing Tarek Harb 🌟who will present our latest work on Lp(a) variability! Roger Blumenthal Johns Hopkins Medicine Johns Hopkins Ciccarone Center Johns Hopkins Cardiology The Osler Medical Residency
Advanced biological 💊Rx💉 reduces ASCVD 🫀events in patients with IBD. Collaborative work Johns Hopkins Cardiology Johns Hopkins Gastroenterology & Hepatology Tarek Harb Lara Chaaban Joanna Melia #ESCCongress2024
Curious about the impact of Lp(a) on #cardiovascular risk? check the #ESCCongress session: esc365.escardio.org/ESC-Congress/s… simultaneous publication on #EHJOpen: doi.org/10.1093/ehjope… #OpenUpYourScience European Society of Cardiology Journals Salvatore De Rosa Magnus Bäck Thorsten Leucker Maciej Banach SABOURETCardiologist
Is it time we routinely remeasure Lp(a) for those w initial levels in the traditional “grey zone” (30-50 mg/dL, 75-125 nmol/L)? Surprising amount of intraindividual variability, and repeat msmt reclassified risk in 53% of pts. Excellent data from Tarek Harb at #ESCCongress2024
Thank you, Maciej Banach, for your outstanding editorial and thoughtful summary of our work on Lp(a) variability. Your insights and comprehensive overview of the current, albeit sparse, literature on this topic are invaluable. EHJOpen Editor-in-Chief Tarek Harb
👉🏻Our study suggests repeat Lp(a) tests 🧪could be crucial for those in the #society_eas intermediate risk group. 53% could be reclassified with a second test. Time to rethink cardiovascular risk assessment. European Atherosclerosis Society EHJOpen Editor-in-Chief American Heart Association American College of Cardiology Tarek Harb
🔥 Following up on Tarek Harb’s fantastic presentation on intraindividual variability in #lpa doi.org/10.1093/ehjope… at #ESC2024, today he delved into 🧬 PPAR-gamma's regulation of Lp(a) gene expression in HepG2 cells. Sam Tsimikas, MD Paul Mason MD Maciej Banach National Lipid Association